ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations. © 2014 The Author(s).

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe / A. Mocroft, P. Reiss, A. Rakhmanova, D. Banhegyi, A.N. Phillips, S. De Wit, M. Ristola, J.D. Lundgren, J. Grarup, O. Kirk, M. Losso, M. Kundro, N. Vetter, R. Zangerle, I. Karpov, A. Vassilenko, O. Suetnov, N. Clumeck, M. Delforge, R. Colebunders, L. Vandekerckhove, V. Hadziosmanovic, K. Kostov, J. Begovac, L. Machala, D. Jilich, D. Sedlacek, J. Nielsen, G. Kronborg, T. Benfield, M. Larsen, J. Gerstoft, T. Katzenstein, A.-.E. Hansen, P. Skinhoj, C. Pedersen, L. Ostergaard, K. Zilmer, J. Smidt, C. Katlama, J.-. Viard, P.-. Girard, J.M. Livrozet, P. Vanhems, C. Pradier, F. Dabis, D. Neau, J. Rockstroh, R. Schmidt, J. van Lunzen, O. Degen, H.J. Stellbrink, M.M. Bickel, J. Bogner, G. Fatkenheuer, J. Kosmidis, P. Gargalianos, G. Xylomenos, J. Perdios, G. Panos, A. Filandras, E. Karabatsaki, H. Sambatakou, F. Mulcahy, I. Yust, D. Turner, M. Burke, S. Pollack, G. Hassoun, S. Maayan, S. Vella, R. Esposito, I. Mazeu, C. Mussini, C. Arici, R. Pristera, F. Mazzotta, A. Gabbuti, V. Vullo, M. Lichtner, A. Chirianni, E. Montesarchio, M. Gargiulo, G. Antonucci, A. Testa, G. D'Offizi, C. Vlassi, M. Zaccarelli, A. Antorini, A. Lazzarin, A. Castagna, N. Gianotti, M. Galli, A. Ridolfo, B. Rozentale, I. Zeltina, S. Chaplinskas, T. Staub, R. Hemmer, V. Ormaasen, A. Maeland, J. Bruun, B. Knysz, J. Gasiorowski, A. Horban, E. Bakowska, A. Grzeszczuk, R. Flisiak, A. Boron-Kaczmarska, M. Pynka, M. Parczewski, M. Beniowski, E. Mularska, H. Trocha, E. Jablonowska, E. Malolepsza, K. Wojcik, F. Antunes, M. Doroana, L. Caldeira, K. Mansinho, F. Maltez, D. Duiculescu, N. Zakharova, S. Buzunova, D. Jevtovic, M. Mokras, D. Stanekova, J. Tomazic, J. Gonzalez-Lahoz, V. Soriano, P. Labarga, J. Medrano, S. Moreno, J.M. Rodriguez, B. Clotet, A. Jou, R. Paredes, C. Tural, J. Puig, I. Bravo, J.M. Gatell, J.M. Miro, P. Domingo, M. Gutierrez, G. Mateo, M.A. Sambeat, A. Blaxhult, L. Flamholc, A. Thalme, A. Sonnerborg, B. Ledergerber, R. Weber, P. Francioli, M. Cavassini, B. Hirschel, E. Boffi, H. Furrer, M. Battegay, L. Elzi, E. Kravchenko, N. Chentsova, V. Frolov, G. Kutsyna, S. Servitskiy, M. Krasnov, A.M. Johnson, D. Mercey, A. Phillips, M.A. Johnson, M. Murphy, J. Weber, G. Scullard, M. Fisher, C. Leen, J. Gatell, B. Gazzard, A. D'Arminio Monforte, A. Cozzi-Lepri, D. Grint, A. Schultze, L. Shepherd, M. Sabin, D. Podlekareva, J. Kjaer, L. Peters, J. Tverland, A.H. Fischer, R. Thiebaut, D. Burger. - In: INFECTION. - ISSN 0300-8126. - 42:4(2014 Aug 01), pp. 757-762. [10.1007/s15010-014-0630-4]

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

M. Galli
Membro del Collaboration Group
;
A. D'Arminio Monforte
Membro del Collaboration Group
;
2014

Abstract

ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations. © 2014 The Author(s).
Adenine; Adult; Anti-HIV Agents; Cohort Studies; Data Collection; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Europe; Female; HIV Infections; Humans; Male; Organophosphonates; Oxazines; Prospective Studies; Drug Utilization
Settore MED/17 - Malattie Infettive
1-ago-2014
6-giu-2014
Article (author)
File in questo prodotto:
File Dimensione Formato  
15010_2014_Article_630.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 292.2 kB
Formato Adobe PDF
292.2 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/774203
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 3
social impact